Stocks / HAE
Is Haemonetics Corporation (HAE) a buy right now?
Haemonetics Corporation · $117
Updated Thu, Oct 8, 6:45 PM ET
Haemonetics Corporation (HAE) at $117 is a Hold. Business quality is good and valuation is stretched. There is no entry signal today.
What should I do?
No active entry signal at the current price — check valuation zones and risk. This is current-state context, not a timing forecast.
What we're seeing
The stock recently jumped about 16%.
Today's price is not a good place to start.
Why this rating on HAE
For Haemonetics Corporation (HAE), worth tracking, but not a clean ownership case yet.
On HAE, today's setup does not provide a high-confidence entry.
If you already own HAE, you can hold your existing position. Today's entry timing does not change the long-term HOLD outlook.
- •Profitability is improving but not yet a strength.
What HAE does
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS…
Common questions
Should I buy Haemonetics Corporation (HAE) stock?
Haemonetics Corporation (HAE) is a Hold. Business quality is good and valuation is stretched. That is the long-term call — not a same-day order.
Is HAE a buy right now?
Haemonetics Corporation (HAE) at $117 is a Hold. Business quality is good and valuation is stretched. There is no entry signal today.
Is Haemonetics Corporation a good company?
Haemonetics Corporation (HAE) looks like a good company — solid business quality, not the top tier. Quality still has to be weighed against valuation and today's setup.
Is Haemonetics Corporation overvalued?
Haemonetics Corporation (HAE) looks expensive. Valuation is stretched versus estimated fair value — the business may still be high quality.
Is now a good time to buy Haemonetics Corporation stock?
There is no entry signal today. On HAE, today's setup does not provide a high-confidence entry. That is today's tape — not the same question as whether Haemonetics Corporation (HAE) is worth owning.
Why is HAE a Hold?
For Haemonetics Corporation (HAE), worth tracking, but not a clean ownership case yet.
Other stock pages
- AALAmerican Airlines Group Inc. · $12.66Long-termAVOIDTodayAVOIDVery Attractive
- AAPLApple Inc. · $343Long-termBUYTodaySTART SMALLFair Value
- ABBABB Ltd · $37.13Long-termHOLDVery Stretched
- ABEVAmbev S.A. · $3.30Long-termBUYVery Attractive
Full report with zones, financials, and today's tape.
Our reports are for informational purposes only and do not constitute financial advice. Investment ratings are calculated using quantitative models and real market data. Report summaries are automatically generated for readability. Always consult a licensed financial advisor before making investment decisions. We are not liable for investment losses.